Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

ADVM

Adverum Biotechnologies (ADVM)

Adverum Biotechnologies Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ADVM
DateTimeSourceHeadlineSymbolCompany
05/09/202421:30GlobeNewswire Inc.Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ADVMAdverum Biotechnologies Inc
05/09/202406:05GlobeNewswire Inc.Adverum Biotechnologies to Participate in Upcoming Fall Investor ConferencesNASDAQ:ADVMAdverum Biotechnologies Inc
13/08/202406:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ADVMAdverum Biotechnologies Inc
13/08/202406:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADVMAdverum Biotechnologies Inc
13/08/202406:05GlobeNewswire Inc.Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate HighlightsNASDAQ:ADVMAdverum Biotechnologies Inc
07/08/202406:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADVMAdverum Biotechnologies Inc
07/08/202406:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADVMAdverum Biotechnologies Inc
07/08/202406:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADVMAdverum Biotechnologies Inc
02/08/202421:00GlobeNewswire Inc.Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
01/08/202422:00GlobeNewswire Inc.Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMDNASDAQ:ADVMAdverum Biotechnologies Inc
18/07/202406:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADVMAdverum Biotechnologies Inc
17/07/202416:45GlobeNewswire Inc.Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual MeetingNASDAQ:ADVMAdverum Biotechnologies Inc
10/07/202422:00GlobeNewswire Inc.Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual MeetingNASDAQ:ADVMAdverum Biotechnologies Inc
19/06/202406:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADVMAdverum Biotechnologies Inc
18/06/202422:00GlobeNewswire Inc.Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA SummitNASDAQ:ADVMAdverum Biotechnologies Inc
12/06/202406:19Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ADVMAdverum Biotechnologies Inc
12/06/202406:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADVMAdverum Biotechnologies Inc
11/06/202422:00GlobeNewswire Inc.Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of DirectorsNASDAQ:ADVMAdverum Biotechnologies Inc
29/05/202404:00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ADVMAdverum Biotechnologies Inc
10/05/202406:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ADVMAdverum Biotechnologies Inc
10/05/202406:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADVMAdverum Biotechnologies Inc
10/05/202406:05GlobeNewswire Inc.Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline HighlightsNASDAQ:ADVMAdverum Biotechnologies Inc
03/05/202422:00GlobeNewswire Inc.Adverum Biotechnologies to Participate in Upcoming May Investor ConferencesNASDAQ:ADVMAdverum Biotechnologies Inc
26/04/202406:05GlobeNewswire Inc.Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific MeetingNASDAQ:ADVMAdverum Biotechnologies Inc
19/03/202407:05GlobeNewswire Inc.Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate UpdatesNASDAQ:ADVMAdverum Biotechnologies Inc
05/03/202408:40Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ADVMAdverum Biotechnologies Inc
29/02/202408:05GlobeNewswire Inc.Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
23/02/202407:47Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ADVMAdverum Biotechnologies Inc
22/02/202407:39Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ADVMAdverum Biotechnologies Inc
16/02/202408:17Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ADVMAdverum Biotechnologies Inc
 Showing the most relevant articles for your search:NASDAQ:ADVM